Special Issue

Oral Biofilm and Microbiome

Message from the Guest Editor

Some early studies revealed a distinction in the microbial profiles of healthy and diseased conditions. Cross-sectional and association studies identified some putative pathogens based on their virulency and strong association with diseased sites. The early interpretation of these findings was that the transition from a healthy to diseased/destructive condition is caused by emergence of specific pathogenic within oral biofilm. However, current evidence suggests that this transition is due to ecological disruption of the commensal oral biofilm or dysbiosis involving polymicrobial synergy. The complexity of the oral microbiome could be summarized in the multifaceted biology of the microbial component, limitation of microbial profiling in diagnostic tools, and complex host–microbial interaction. In recent years, the development of new technology platforms and the advanced understanding of microbial pathogenicity have paved the way for more sophisticated antimicrobial and specifically antibiotic approaches. This issue aims to cover recent advances in the oral microbiome as well as virulome detection and profiling and the impact of such knowledge in therapy strategies.

Guest Editor

Dr. Ahmed El-Awady

Department of Periodontics, The Dental College of Georgia, Augusta University, Augusta, GA 30912, USA

Deadline for manuscript submissions

closed (31 March 2022)

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/si/84287

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/antibiotics

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/journal/antibiotics

About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

MDPI